Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: Retrospective clinical observation

International Immunopharmacology

Volumn 21, Issue 2, 2014, Pages 396-405

  Zhang, Guoqing ^a   Zhao, Hong ^a   Wu, Jianyu ^a   Li, Jingyu ^a   Xiang, Yan ^a   Wang, Gang ^a   Wu, Liangliang ^a   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adoptive immunotherapy; NKTm cells; NSCLC; Retrospective clinical observation

Indexed keywords

AMINOTRANSFERASE; BETA1 INTEGRIN; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CREATININE; HEMOGLOBIN; LEUKOCYTE ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CASE CONTROL STUDY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL PROLIFERATION; CELL TRANSFER; CHILL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTES MIXED EFFECTOR CELL IMMUNOTHERAPY; EFFECTOR CELL; ERYTHEMA; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MALE; NATURAL KILLER T CELL; OVERALL SURVIVAL; PAPULE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE COUNT; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; MONONUCLEAR CELL; NATURAL KILLER CELL; PROCEDURES; SURVIVAL RATE;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84902356724     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.04.026     Document Type: Article

References (45)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics CA Cancer J Clin 59 2009 225 249
2. S. Collaud, R. Stahel, I. Inci, S. Hillinger, D. Schneiter, and P. Kestenholz et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage Lung Cancer 78 3 2012 234 238
3. C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, and C. Wang et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label randomised, phase 3 study Lancet Oncol l2 8 2011 735 742
4. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, and H. Isobe et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 25 2010 2380 2388
5. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 2009 947 957
6. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, and E. Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 3 2012 239 246
7. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2 2010 121 128
8. A.T. Shaw, B.Y. Yeap, B.J. Solomon, G.J. Riely, J. Gainor, and J.A. Engelman et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
9. A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crinó, and M.J. Ahn et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 25 2013 2385 2394
10. L. Gattinoni, D.J. Powell Jr., S.A. Rosenberg, and N.P. Restifo Adoptive immunotherapy for cancer: building on success Nat Rev Immunol 6 2006 383 393
11. K.K. Ballen, G. Colvin, B.R. Dey, D. Porter, P. Westervelt, and T.R. Spitzer et al. Cellular immune therapy for refractory cancers: novel therapeutic strategies Exp Hematol 33 2005 1427 1435 (Pubitemid 41773842)
12. M.Z. Papa, J.J. Mulé, and S.A. Rosenberg Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastasis from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types Cancer Res 46 1986 4973 4978 (Pubitemid 16008249)
13. D.D. Schoof, B.A. Gramolini, D.L. Davidson, A.F. Massaro, R.E. Wilson, and T.J. Eberlein Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells Cancer Res 48 1988 5007 5010
14. Y.S. Yun, M.E. Hargrove, and C.C. Ting In vivo antitumor activity of anti-CD3 induced activated killer cells Cancer Res 49 1989 4770 4774 (Pubitemid 19213622)
15. R.B. Herberman Cancer immunotherapy with natural killer cells Semin Oncol 29 2002 27 30 (Pubitemid 34620432)
16. H. Klingemann, and L. Boissel Targeted cellular therapy with natural killer cells Horm Metab Res 40 2008 122 125 (Pubitemid 351363423)
17. H. Guo, and X. Qian Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects Onkologie 33 2010 389 395
18. D.N. Hart, and G.R. Hill Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma Immunol Cell Biol 77 1999 451 459 (Pubitemid 29476916)
19. L.D. Cranmer, K.T. Trevor, and E.M. Hersh Clinical applications of dendritic cell vaccination in the treatment of cancer Cancer Immunol Immunother 53 2004 275 306 (Pubitemid 38392306)
20. M.J. Besser, R. Shapira-Frommer, A.J. Treves, D. Zippel, O. Itzhaki, and L. Hershkovitz et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clin Cancer Res 16 2010 2646 2655
21. L.T. Nguyen, P.H. Yen, J. Nie, N. Liadis, D. Ghazarian, and A. Al-Habeeb et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs) PLoS ONE 5 2010 e13940
22. P. Olioso, R. Giancola, M. Di Riti, A. Contento, P. Accorsi, and A. Iacone Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial Hematol Oncol 27 2009 130 139
23. C. Wu, J. Jiang, L. Shi, and N. Xu Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer Anticancer Res 28 2008 3997 4002
24. D. Sangiolo Cytokine induced killer cells as promising immunotherapy for solid tumors J Cancer 2 2011 363 368
25. A. Yasuda, S. Kondo, T. Nagumo, H. Tsukamoto, Y. Mukudai, and K. Umezawa et al. Anti-tumor activity of NKTm against human carcinoma cell lines in vitro Acad J PLA Postgrad Med Sch 29 2008 349 351
26. J.H. You, J.L. Yang, S.C. Jiao, X.S. Lin, L.L. Wu, and G. Wang Combined cytotoxic effects of NK and T lymphocytes and cisplatin on human breast cancer cell line MDA-MB-231 in vitro Acad J PLA Postgrad Med Sch 30 2009 378 385
27. J.Y. Li, S.C. Jiao, X.S. Lin, Q.G. Zhang, and J.L. Zhang Effect of combined use of NKTm cells and cisplatin on tumoricidal activity against human pulmonal giant cell carcinoma cells in vitro Acad J PLA Postgrad Med Sch 8 2008 346 348
28. P.D. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells Adv Immunol 49 1991 281 355
29. C.H. June Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 2007 1466 1476 (Pubitemid 46871329)
30. I.G. Schmidt-Wolf, P. Lefterova, V. Johnston, D. Huhn, K.G. Blume, and R.S. Negrin Propagation of large numbers of T cells with natural killer cell markers Br J Haematol 87 1994 453 458 (Pubitemid 24230007)
31. T. Leemhuis, S. Wells, C. Scheffold, M. Edinger, and R.S. Negrin A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Biol Blood Marrow Transplant 11 2005 181 187 (Pubitemid 40287916)
32. I.G. Schmidt-Wolf, S. Finke, B. Trojaneck, A. Denkena, P. Lefterova, and N. Schwella et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma Br J Cancer 81 1999 1009 1016 (Pubitemid 29516145)
33. M. Hara, Y. Matsuzaki, T. Shimizu, M. Tomita, T. Ayabe, and Y. Enomoto et al. Preoperative peripheral naïve/memory ratio and prognosis of non small-cell lung cancer patients Ann Thorac Cardiovasc Surg 13 2007 384 390
34. A.M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 2003 606 612 (Pubitemid 36182591)
35. C.M. Costantino, C.M. Baecher-Allan, and D.A. Hafler Human regulatory T cells and autoimmunity Eur J Immunol 38 2008 921 924
36. S.S. Patel, A.D. Duby, D.L. Thiele, and P.E. Lipsky Phenotypic and functional characterization of human T cell clones J Immunol 141 1988 3726 3736
37. M.R. Campanero, R. Pulido, M.A. Ursa, M. Rodríguez-Moya, M.O. de Landázuri, and F. Sánchez-Madrid An alternative leukocyte homotypic adhesion mechanism, LFA-1/ICAM-1-independent, triggered through the human VLA-4 integrin J Cell Biol 110 1990 2157 2165
38. K. Chansky, J.P. Sculier, J.J. Crowley, D. Giroux, J. Van Meerbeeck, and P. Goldstraw [The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer] Zhongguo Fei Ai Za Zhi 13 2010 9 18
39. F.C. Detterbeck, D.J. Boffa, and L.T. Tanoue The new lung cancer staging system Chest 136 2009 260 271
40. A. Cassano, and A. Pompueci Multimodality treatment of non-small cell lung cancer brain metastasis: long term outcome J Clin Oncol 24 2006 17046
41. Y. Oh, S. Taylor, B.N. Bekele, J.M. Debnam, P.K. Allen, and D. Suki et al. Number of metastatic sites is strong predictor of survival in patients with non small cell lung cancer with or without brain metastases Cancer 115 2009 2930 2938
42. G.M. Videtic, C.A. Reddy, S.T. Chao, T.W. Rice, D.J. Adelstein, and G.H. Barnett et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification Int J Radiat Oncol Biol Phys 75 2009 1141 1147
43. C. Manegold Chemotherapy for advanced non-small cell lung cancer: standards Lung Cancer 34 2001 S165 S170
44. C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, and C. Wang et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label randomized, phase 3 study Lancet Oncol 2 2011 735 742
45. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, and E. Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246